Cubical Pharmaceutical: Some products are expected to be selected in the 12th batch of national drug centralized procurement.

Cubex Pharmaceutical announced that the company is participating in the national organized centralized drug procurement application, with the long-acting capsule of doxazosin mesylate and azilsartan medoxomil tablets expected to be selected. In 2025, the sales revenue for the long-acting capsule of doxazosin mesylate is projected to be 103.4095 million yuan, accounting for 6.66% of that year's revenue; the azilsartan medoxomil tablets were approved for market launch on May 19, 2026, and have not yet generated revenue. The procurement cycle will run from the date of the selection results until December 31, 2029. If a procurement contract is subsequently signed and implemented, it will have a positive impact on the companys performance. However, the expected selection results still need to be publicly confirmed, and there are uncertainties regarding subsequent matters.